Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70060 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Marco Picardi und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged patients who were scheduled to receive six BV + AVD for newly diagnosed advanced stage cHL. This is the largest cohort of Ya&A reported to date including 150 patients from four clinical institutions in Southern Italy, all of which employed structured supportive care programs for HL. Fifty patients (30%) had at least one ECHELON‐1 ineligibility criterion, including comorbidities and/or adverse performance status. All 150 patients underwent BV + AVD with a median relative dose intensity of 100% (dose reduction and/or discontinuation ≥ 15%, in 11% of them). At end‐of‐treatment (EoT) FDG‐PET, 93% (140/147) of patients (three did not undergo EoT FDG‐PET due to early grade 5 toxicity) achieved a complete response (95% CI, 88.1–96.8). Altogether, four patients (2.7%) received consolidation radiotherapy of residual nodal masses with a Deauville score of 4. Grade ≥ 2 peripheral neuropathy, cardiotoxicity, and febrile neutropenia were reported by 13%, 7%, and 3% of patients, respectively. With a 24 month median follow‐up, PFS in the entire analyzed population was 91% (95% CI, 0.864–0.958). In Ya&A with high‐risk cHL, our data suggest that a BV‐driven strategy (without bleomycin and consolidation radiotherapy) is an effective up‐front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
- Department of Public Health, Federico II University Medical School Naples, Naples, Italy.
- Department of Advanced Biomedical Sciences, Federico II University Medical School, Naples, Italy.
- Department of Translational Medical Sciences, Federico II University Medical School, Naples, Italy.
- Hematology Unit, Antonio Cardarelli Hospital of National Importance, Naples, Italy.
- Hematology Unit, Hospital Andrea Tortora, Pagani, Italy.
ORCID-Profile: Annamaria Vincenzi, Novella Pugliese, Carlo Gabriele Tocchetti
Zitieren
APA
Picardi, M., Vincenzi, A., Giordano, C., Pugliese, N., Scarpa, A., Lombardi, A., Vigliar, E., Troncone, G., Cappiello, R., Mascolo, M., Esposito, G., Prastaro, M., Santoro, C., Esposito, R., Tocchetti, C. G., Mainolfi, C., Fonti, R., Del Vecchio, S., Trastulli, F., …, & Pane, F. (2026). Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers. European Journal of Haematology. https://doi.org/10.1111/ejh.70060
Vancouver
Picardi M, Vincenzi A, Giordano C, Pugliese N, Scarpa A, Lombardi A, et al. Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers. European Journal of Haematology. 2026. doi:10.1111/ejh.70060
BibTeX
@article{Picardi2026,
author = {Picardi, Marco and Vincenzi, Annamaria and Giordano, Claudia and Pugliese, Novella and Scarpa, Alessia and Lombardi, Assunta and Vigliar, Elena and Troncone, Giancarlo and Cappiello, Rosaria and Mascolo, Massimo and Esposito, Giovanni and Prastaro, Maria and Santoro, Ciro and Esposito, Roberta and Tocchetti, Carlo Gabriele and Mainolfi, Ciro and Fonti, Rosa and Del Vecchio, Silvana and Trastulli, Fabio and Annunziata, Mario and Iula, Rossella and Califano, Catello and Carchia, Marianna and Persico, Marcello and Salemme, Alessia and Nicolai, Emanuele and Soricelli, Andrea and Salvatore, Marco and Pane, Fabrizio},
title = {Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70060}
}
EUVIMED